Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718731 · ClinicalTrials.gov registry record · Phase 1
Study GSI-136 in Healthy Young and Healthy Elderly Subjects
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00718731 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 80 participants.
The verdict
NCT00718731, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a first-in-humans study of GSI-136, a drug being developed for the treatment of Alzheimer Disease. The main purpose of this study is to determine whether GSI-136 is safe and tolerable in healthy young and healthy elderly subjects. The amount of drug in the body and the effects of the drug on the body will also be evaluated at certain timepoints.
Interventions
- OTHER Placebo
- DRUG GSI-136
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00718731
The ClinicalTrials.gov registry entry for NCT00718731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00718731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00718731 about?
NCT00718731 is a clinical study titled "Study GSI-136 in Healthy Young and Healthy Elderly Subjects". This is a first-in-humans study of GSI-136, a drug being developed for the treatment of Alzheimer Disease. The main purpose of this study is to determine whether GSI-136 is safe and tolerable in healthy young and healthy elderly subjects. The amount of drug in the body and the effects of the drug on...
What is the current status of trial NCT00718731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2008-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00718731?
The interventions under investigation include: Placebo (OTHER), GSI-136 (DRUG).
Who is sponsoring clinical trial NCT00718731?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.